Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Nanmeng Yu"'
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 7, Iss 3, Pp 205-209 (2024)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive hematologic malignancy with limited treatment options. Currently, standard treatment strategies include clinical trials; chemotherapy regimens such as hyperfract
Externí odkaz:
https://doaj.org/article/56b26804586548d6930bb80ae7f6d88c
Publikováno v:
Journal of Immunotherapy & Precision Oncology; Aug2024, Vol. 7 Issue 3, p205-209, 5p
Publikováno v:
Cancer Research. 83:3313-3313
Background: There is a need for better prognostic biomarkers for PD1-based therapy. Quantifying the fractional occupancy (FO) of PD1 by PDL1, and PDL1 by PD1, in tumor can be a potential biomarker. We previously reported on an RNA aptamer-based assay
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f19ec275308294936d340a2755855d93
https://doi.org/10.1158/1538-7445.am2023-3313
https://doi.org/10.1158/1538-7445.am2023-3313
Autor:
Bradley T. Loeffler, Taher Abu Hejleh, Mary Pasquinelli, Timothy L. Sita, Ryan Nguyen, Sarah L. Mott, Tim J. Kruser, Muhammad Furqan, Adithya Chennamadhavuni, Nasser H. Hanna, Melissa Yan, Lawrence Eric Feldman, Nanmeng Yu, Josiah An
Publikováno v:
Translational Lung Cancer Research. 10:3608-3615
Background STK11 mutation (STK11m ) in patients (pts) with stage IV non-small cell lung cancer (NSCLC) is associated with inferior survival and poor response to immune checkpoint inhibitors (ICI). The significance of STK11m in stage III NSCLC pts tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ecd1ee7adfc7a01bf19cf21fc86b9f4
https://doi.org/10.21037/tlcr-21-177
https://doi.org/10.21037/tlcr-21-177
Autor:
Josiah, An, Melissa, Yan, Nanmeng, Yu, Adithya, Chennamadhavuni, Muhammad, Furqan, Sarah L, Mott, Bradley T, Loeffler, Timothy, Kruser, Timothy L, Sita, Lawrence, Feldman, Ryan, Nguyen, Mary, Pasquinelli, Nasser H, Hanna, Taher, Abu Hejleh
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: STK11 mutation (STK11(m)) in patients (pts) with stage IV non-small cell lung cancer (NSCLC) is associated with inferior survival and poor response to immune checkpoint inhibitors (ICI). The significance of STK11(m) in stage III NSCLC pts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::25b76e738d193ca9336c7b26a9745724
https://pubmed.ncbi.nlm.nih.gov/34584860
https://pubmed.ncbi.nlm.nih.gov/34584860
Autor:
Nanmeng Yu, Ryan Nguyen, Mary Pasquinelli, Lawrence Eric Feldman, Timothy L. Sita, Josiah An, Adithya Chennamadhavuni, Melissa Yan, Muhammad Furqan, Taher Abu Hejleh, Tim J. Kruser, Nasser H. Hanna
Publikováno v:
Journal of Clinical Oncology. 38:9033-9033
9033 Background: STK11 mutation ( STK11m) in patients with stage IV NSCLC is associated with inferior survival and poor response to immune check point inhibitors (ICI). The significance of STK11m in patients (pts) with stage III NSCLC treated with co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ed386eeb75bddd8769cfd809411740a
https://doi.org/10.1200/jco.2020.38.15_suppl.9033
https://doi.org/10.1200/jco.2020.38.15_suppl.9033
Publikováno v:
Journal of Virology. 89:5250-5263
A major challenge to oncolytic virus therapy is that individual cancers vary in their sensitivity to oncolytic viruses, even when these cancers arise from the same tissue type. Variability in response may arise due to differences in the initial genet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::926492c9f8047fae4b153181d6659581
https://doi.org/10.1128/jvi.00257-15
https://doi.org/10.1128/jvi.00257-15
Autor:
Guorui Deng, Katherine J Perschbacher, Jeremy A Sandgren, Nanmeng Yu, Sabrina M Scroggins, Eric J Devor, Donna A Santillan, Katherine N Gibson-Corley, Curt D Sigmund, Anne E Kwitek, Mark K Santillan, Justin L Grobe
Publikováno v:
Hypertension. 70
Preeclampsia (PE) is a cardiovascular disorder of late pregnancy characterized by pregnancy-specific onset of hypertension and proteinuria. Although initiating events leading to PE development remain unclear, emerging studies suggest arginine vasopre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8986105252f00e0d6600a79bd4181a45
https://doi.org/10.1161/hyp.70.suppl_1.p261
https://doi.org/10.1161/hyp.70.suppl_1.p261
Autor:
Nanmeng Yu1, Puckett, Shelby1, Antinozzi, Peter A.1, Cramer, Scott D.2, Lyles, Douglas S.1 dlyles@wakehealth.edu
Publikováno v:
Journal of Virology. May2015, Vol. 89 Issue 10, p5250-5263. 14p.
Publikováno v:
Clinical Trials Week; 9/16/2024, p1877-1877, 1p